Prelude Therapeutics Inc (PRLD) stock
Close on Nov 11, 2026Market cap $301.66MP/E –Yield –
Prelude Therapeutics Inc grew revenue 220.3% to $22.42M over the twelve months to Jun 30, 2026. Free cash flow was -$33.26M. At the latest close the market valued the company at $301.66M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $301.66M
- P/E ratio
- –
- Price to sales
- 13.45
- Price to book
- 2.26
- Dividend yield
- –
- Free cash flow yield
- -11.02%
Fundamentals
- Revenue
- $22.42M
- Net income
- -$60.49M
- EPS, diluted
- -$0.74
- Free cash flow
- -$33.26M
- Book value per share
- $1.36
- Diluted shares
- 98M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $3.76
- Open
- $3.80
- Day's range
- $3.73 – $4.10
- Volume
- 295,281
- Average volume (20 days)
- 374,765
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.24
- 52-week range
- $1.21 – $6.83
- RSI (14 days)
- 48.1
- Volatility (1 year)
- 109.0%
- Relative volume
- 0.66×
- WACC
- 11.1%
On 2 of our idea lists: More cash than they're worth, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRLD | S&P 500 | Difference | PRLD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.8% | -2.4% | −0.4 pts | ||
| 3 months | -28.9% | -1.2% | −27.8 pts | ||
| Year to date | +30.3% | +12.3% | +18.1 pts | ||
| 1 year | +180.0% | +12.4% | +167.6 pts | ||
| 3 years | +25.6% | +78.8% | −53.2 pts | +7.9% | +21.4% |
| 5 years | -77.4% | +75.2% | −152.6 pts | -25.8% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Prelude Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Results
- News
About Prelude Therapeutics
Pharmaceutical Preparations
Prelude Therapeutics Incorporated is a clinical-stage precision oncology biopharmaceutical company focused on discovering and developing targeted cancer therapies. The company identifies compelling biological target mechanisms, such as transcriptional regulation and cell proliferation signaling pathways, to design new chemical entities. Its product candidate pipeline utilizes multiple therapeutic modalities, including small-molecule inhibitors, targeted protein degraders, and precision antibody-drug conjugates. Prelude focuses its development programs on underserved patient populations with solid tumors and hematological malignancies that have high unmet medical needs. Key programs include lead candidates such as PRT12396, a selective JAK2 inhibitor, and preclinical candidates targeting KAT6A as well as mutated calreticulin.
Company profile, executives and historyPrelude Therapeutics stock: common questions
What is Prelude Therapeutics's stock price?
PRLD closed at $3.78 on Nov 11, 2026, up 0.53% on the day. Over the past 52 weeks it traded between $1.21 and $6.83.
What is Prelude Therapeutics's market cap?
Prelude Therapeutics was worth $301.66M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PRLD's P/E ratio?
Prelude Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.74), so it has no meaningful P/E ratio.
How much revenue does Prelude Therapeutics make?
Prelude Therapeutics reported revenue of $22.42M for the twelve months to Jun 30, 2026, up 220.3% from a year earlier.
Does Prelude Therapeutics pay a dividend?
No. Prelude Therapeutics has not paid a cash dividend over the last twelve months.
When does Prelude Therapeutics report earnings next?
Prelude Therapeutics is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PRLD stock performed over the past year?
Including dividends, PRLD returned +180.0% over the past year, against +12.4% for the S&P 500.
How many PRLD shares are sold short?
4M shares were sold short at the latest FINRA report, 8.80% of the float, or 9.1 days of average trading volume.
Who are Prelude Therapeutics's competitors?
Companies most similar to Prelude Therapeutics by business, industry and size include TNGX, FHTX, JANX, CBIO, PYXS.
See a number that looks wrong?